OCGN Q3 FY26 earnings call: key takeaways

• OCGN reported a net loss of $0.01 per share for the third quarter of 2026, which matched the consensus estimate of -$0.06 (15:02)

Results vs expectations

What changed since last quarter

• The company raised its cash runway guidance to 2028, up from previous expectations. (13:54)
• OCGN announced the completion of enrollment in the OCU400 Phase III trial, with top-line data expected in Q1 2027. (7:07)
• The company provided more details on its LARTA approval in the Bahamas, including potential commercial revenue and patient access. (20:20)

What analysts pressed on

• Whether the DMC's recommendation for the Stargardt program will impact the trial's design or timeline. (17:48)
• Concerns about the statistical significance of the interim analysis for the Stargardt program. (25:08)
• Questions about the commercial viability and pricing of the Bahamas program. (27:41)

In their words

• We remain on track to file three BLAs by 2028 (7:07)
• We are continuing the study until month 12, and we're looking forward to release the data by second half or second quarter next year (18:51)
• We believe, based on this earlier data, we should also see, you know, similarly in our trend on the structural and functional improvement in those subjects (34:12)